Complying with REMS Training and Documentation Requirements

Michael Singel, PharmD, discusses the logistics of complying with the Risk Evaluation and Mitigation Strategy program for bispecific antibodies at his institution and addresses training and documentation requirements.

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

Now Viewing

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

Related Videos

Related Content

Advertisement

November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor

November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

October 24th 2024

Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma

Alana Hippensteele, Managing Editor

Related Content

Advertisement

November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor

November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

October 24th 2024

Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma

Alana Hippensteele, Managing Editor